Author's response to reviews

Title: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer.

Authors:

Greg M Arndt (garndt@medau.jnj.com)
Lesley Dossey (dossey@earthlink.net)
Lara M Cullen (lara.cullen@appliedbiosystems.com)
Angela Lai (angela.lai@appliedbiosystems.com)
Riki Druker (riki.druker@osmr.nws.gov.au)
Michael Eisbacher (meisbach1@medau.jnj.com)
Chunyan Zhang (czhang15@medau.jnj.com)
Nham Tran (ntran@med.usyd.edu.au)
Hongtao Fan (hfan@cntus.jnj.com)
Kathy Retzlaff (shamading@yahoo.com)
Anton Bittner (abittner@prdus.jnj.com)
Mitch Raponi (mraponi1@its.jnj.com)

Version: 4 Date: 18 August 2009

Author’s response to reviews:

Dear Dr Marshall

Thank you for your favorable review of our manuscript. We also thank the reviewer’s for their helpful comments.

We have modified the final sentences in the Discussion to highlight the main limitation of this study as follows: “It should be noted however, that our results were limited to one metastatic CRC model. To further validate our findings additional metastatic models should be investigated for a similar phenotypic impact. Nevertheless, investigators contemplating the use of miR-145 as a therapeutic strategy for CRC should keep in mind that specific miRNAs may have opposing biological functions at different stages of tumor development.”

We have also incorporated the Methods section between the Background and Results sections as requested.

Sincerely

Mitch Raponi, Ph.D.